Preventive Vaccines Market Report 2026

Preventive Vaccines Market Overview

• Preventive Vaccines market size has reached to $83 billion in 2025 • Expected to grow to $131.27 billion in 2030 at a compound annual growth rate (CAGR) of 9.8% • Growth Driver: Surge In Infectious Diseases Fueling The Growth Of The Market Due To Rising Disease Prevalence And Urgent Need For Effective Control • Market Trend: Advancements In Vaccine Technology Drive Enhanced Protection For High-risk Populations • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Preventive Vaccines Market?

Preventive vaccines are biological preparations designed to protect individuals from infectious diseases by stimulating the immune system to recognize and fight specific pathogens. They are administered before exposure to a disease-causing agent to prevent infection or reduce its severity. Preventive vaccines play a crucial role in public health by controlling the spread of contagious diseases. The main types of preventive vaccines include live or attenuated vaccines, inactivated vaccines, toxoid vaccines, subunit vaccines, conjugate vaccines, DNA vaccines, and recombinant vector vaccines. Live or attenuated vaccines refer to vaccines made from weakened forms of the virus or bacteria that stimulate a strong and lasting immune response without causing disease. The disease types include pneumococcal, poliovirus, hepatitis, influenza, measles, rubella, and others, with distribution channels including hospitals, clinics, pharmacies, and other healthcare outlets. The age groups covered are pediatric, adult, and geriatric.

What Is The Preventive Vaccines Market Growth Forecast?

The preventive vaccines market size is expected to see strong growth in the next few years. It will grow to $131.27 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to development of next-generation vaccine platforms, rising global population and urbanization, increasing outbreak preparedness initiatives, expansion of adult immunization programs, growth in public–private partnerships in vaccine development. Major trends in the forecast period include expansion of national immunization programs, rising focus on preventive healthcare and disease control, increasing demand for pediatric and geriatric vaccination, growth in combination and multivalent vaccines, strengthening cold chain and vaccine storage infrastructure.

Global Preventive Vaccines Market Segmentation

1) By Type: Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines 2) By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types 3) By Age Group: Pediatric, Adult, Geriatric 4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Other Distribution Channels Subsegments: 1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guérin (BCG) Vaccine 2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine 3) By Toxoid Vaccines: Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine 4) By Subunit Vaccines: Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine 5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine 6) By DNA Vaccines: Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines 7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines

What Is The Driver Of The Preventive Vaccines Market?

The increasing prevalence of infectious diseases is expected to propel the growth of the preventive vaccines market going forward. Infectious diseases refer to illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites that can be transmitted from person to person or through the environment. The rise in prevalence of infectious diseases is driven by factors such as increasing urbanization, global travel, and antimicrobial resistance, which facilitate faster spread and harder control of infections. Preventive vaccines help control infectious diseases by stimulating the immune system to recognize and fight pathogens before infection occurs, thereby reducing disease incidence and transmission. For instance, in 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that the number of newly diagnosed TB (tuberculosis) cases worldwide reached 8.2 million in 2023, an increase from 7.5 million in 2022. Therefore, the increasing prevalence of infectious diseases is driving the growth of the preventive vaccines industry.

Key Players In The Global Preventive Vaccines Market

Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.

Global Preventive Vaccines Market Trends and Insights

Major companies operating in the preventive vaccines market are focusing on advancements in vaccine technology, such as advanced mRNA technology platforms, to enhance vaccine efficacy, improve safety profiles, enable faster development and manufacturing, and provide broader protection against emerging variants of infectious diseases. Advanced mRNA technology platforms refer to cutting-edge methods that use messenger RNA to instruct cells to produce specific proteins, triggering a targeted immune response. For instance, in March 2025, Moderna Inc., a US-based biotechnology company, announced FDA approval for mRNA-1283 (mNEXSPIKE), a new COVID-19 vaccine. It is authorized for adults aged 65 and older and individuals aged 12–64 with one or more CDC-defined risk factors. The launch of mNEXSPIKE marks a significant advancement in next-generation mRNA vaccine technology, offering improved stability and ease of storage compared to earlier versions. This development is expected to enhance vaccine accessibility and distribution, particularly in underserved and remote areas.

What Are Latest Mergers And Acquisitions In The Preventive Vaccines Market?

In April 2024, European LifeCare Group, a UK-based vaccination company, acquired PreventVaccins B.V. for an undisclosed amount. Through this acquisition, European LifeCare Group expanded its European footprint and vaccination services through the acquisition of PreventVaccins B.V., enhancing its presence in the Dutch market. PreventVaccins B.V. is a Netherlands-based biotechnology company that focuses on the development of preventive vaccines, especially for infectious diseases.

Regional Insights

North America was the largest region in the preventive vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Preventive Vaccines Market?

The preventive vaccines market consists of sales of toxoid vaccines, plant-based vaccines, and combination vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Preventive Vaccines Market Report 2026?

The preventive vaccines market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the preventive vaccines industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.